Target intelligence / Profile preview

Trans-activation response element of human immunodeficiency virus RNA (TAR element)

Target
TAR element
Molecular classification
RNA structural element, Regulatory RNA, Pre-microRNA (in some contexts)
01

Overview

The **Trans-activation response (TAR) element of HIV RNA** is a highly conserved structured RNA hairpin present at the 5′ and 3′ ends of all HIV-1 transcripts[1][2][3][4][5]. It primarily functions as an essential regulatory switch, binding the viral Tat protein to enhance the processivity of RNA polymerase II at the HIV long terminal repeat (LTR) promoter, greatly increasing transcription of the viral genome[1][2][4][5]. Besides its primary transcriptional regulatory role, TAR is involved in multiple steps of the HIV lifecycle, including regulating translation (repression), promoting genome packaging, participating in reverse transcription, and acting as an inhibitor of the host antiviral PKR protein[1][3]. TAR RNA can also be processed by Dicer to generate a microRNA-like molecule, potentially contributing to viral latency and suppression of apoptosis in infected cells[5][6]. Its essential and multifaceted nature makes it an attractive, though technically challenging, target for antiviral drug development[1][5][6].

Other names
HIV TARTAR RNAHIV-1 TARHIV-1 TAR RNATrans-activation response element
02

Mechanism of action

Inhibition of Tat–TAR interaction blocks transcriptional elongation in HIV, suppressing viral replication[1][2][5]. Small molecules, oligonucleotides or other ligands may bind TAR RNA, preventing Tat binding or altering RNA structure to inhibit function[1].

03

Biological functions

Regulation of HIV-1 transcription (Tat-mediated transcriptional activation)Regulation of viral genome packagingModulation of translation (translational repression)Inhibition of host PKR (protein kinase R) to evade immune responseGeneration of viral microRNA (miRNA) involved in host/viral gene silencing
04

Disease associations

Infection (critical for HIV-1 replication and persistence)Immune evasion (by inhibiting PKR and producing miRNA)
05

Safety considerations

Therapeutic targeting of TAR RNA poses challenges such as avoiding off-target effects and the need to specifically penetrate HIV-infected cells
06

Interacting drugs

There are no FDA-approved drugs that directly target TAR RNA clinically, but experimental small molecules and antisense oligonucleotides have been studied as Tat/TAR inhibitors in the research setting
07

Biomarkers

TAR-derived viral miRNA can serve as a biomarker for HIV latency or infection in research settings

Beyond the preview

Go deeper on Trans-activation response element of human immunodeficiency virus RNA (TAR element).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans-activation response element of human immunodeficiency virus RNA (TAR element).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call